Andrew Sumnicht, MD
Ophthalmology · Edmonds, WANPI 1306335435
Payments from drug & device makers
Across 60 payments — averaging $46.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$584
- Glaukos Corporation$469
- Oyster Point Pharma, Inc.$205
- Amgen$196
- Sight Sciences, Inc.$191
- Sun Pharmaceutical Industries Inc.$189
- plus $931 from 10 others
What the payments were for
- Food & beverage$2,765100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 9 | $584 |
| Glaukos Corporation | 6 | $469 |
| Oyster Point Pharma, Inc. | 3 | $205 |
| Amgen(2 entities) | 4 | $196 |
| Sight Sciences, Inc. | 3 | $191 |
| Sun Pharmaceutical Industries Inc. | 8 | $189 |
| Dompe US, Inc. | 2 | $157 |
| Rxsight Inc | 1 | $146 |
| Bausch & Lomb Americas Inc. | 7 | $131 |
| Carl Zeiss Meditec USA, Inc. | 2 | $129 |
| Rayner Intraocular Lenses Limited | 3 | $110 |
| AbbVie | 5 | $104 |
| Regeneron Healthcare Solutions, Inc. | 3 | $81 |
| Novartis | 2 | $27 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$163
- iStent Infinite$150
- iDoseTR$150
- RXSIGHT CONTACT LENS$146
- RXSIGHT INJECTOR CARTRIDGE$146
- RXSIGHT INJECTOR HANDPIECE$146
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$146
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$146
- Clareon$144
- OMNI(R) SURGICAL SYSTEM (US)$140
- AcrySof$132
- Rocklatan$125
- Rhopressa$125
- TEPEZZA$125
- Oxervate$123
- CALLISTO eye$116
- CEQUA$110
- iStent Trabecular Micro-Bypass System Model iS3$110
How this compares
$2,765 in reported general payments places this provider in the 70th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 87 | $105,483 |
| Cyclosporine | 42 | $18,003 |
| RhopressaNetarsudil Mesylate | 15 | $6,677 |
| Prednisolone Acetate | 186 | $5,805 |
| Fluorometholone | 64 | $4,078 |
| Latanoprost | 224 | $2,664 |
| ValacyclovirValacyclovir Hcl | 36 | $1,567 |
| Timolol Maleate | 45 | $1,238 |
| Ketorolac Tromethamine | 55 | $1,127 |
| ErythromycinErythromycin Base | 53 | $792 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 63 | $762 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 49 | $757 |
| Brimonidine Tartrate | 65 | $622 |
| Ofloxacin | 26 | $308 |
| Acetazolamide ErAcetazolamide | 14 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $104 | $105,48387 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $24 | $6,67715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Edmonds
- Robert WirthlinSpokane$2.4M
- Laura PerimanSeattle$1.9M
- Todd SchneidermanSilverdale$602K
- Sheldon CowenSeattle$560K
- Todd KlesertBellevue$506K
- Jason JonesSpokane$386K
- David SpinakSilverdale$351K
- Jay RuddPuyallup$291K
- Raghu MudumbaiSeattle$284K
- David SapersteinBellevue$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.